I've been reading about these changes. What is the economic impact on genetics companies that don't own the sexing technology, like URUS Group or its subsidiaries, such as CRI? I presume they were using ST's technology for sex-sorted semen. Could you discuss the impact of sexing on the economics of genetics businesses?

It went from having no cost to becoming a major part of the expense line for companies like the URUS Group, Select Sires, and virtually all the different companies, including Genus. In the early phases, Genus worked with Sexing Technologies until they developed their own. This became a significant expense factor early on. Initially, there was a big price premium in the marketplace for that. Over time, the price has eroded somewhat, but the production efficiency of producing sexed semen has increased greatly. It's probably a trade-off between those two. Can I take a minute to talk about production efficiency? When you look at the economics of sexed semen, that's an important factor.

I've been reading about these changes. What is the economic impact on genetics companies that don't own the sexing technology, like URUS Group or its subsidiaries, such as CRI? I presume they were using ST's technology for sex-sorted semen. Could you discuss the impact of sexing on the economics of genetics businesses?

Early on, when producing sexed semen, if we were getting, say, five straws from a bull for conventional semen, we might only get one straw of sorted semen from the same amount of raw semen. It was a big sacrifice in terms of production. Efficiency has improved significantly now, and it depends on the bull, but it's much closer to one-to-one now than it has been. So, you aren't sacrificing any amount of doses, at least with the ST product that I'm familiar with.